Lusis Launches Urinary Tract Infection (UTI) and Antimicrobial Resistance (AMR) Solutions

Lusis Biosciences, a leading provider of molecular reagents and instruments, announces the launch of VeraPoint Urinary Max and VeraPoint AMR Max qPCR panels. These solutions are engineered to deliver unmatched efficiency, precision, and modular flexibility to meet the evolving needs of laboratories.

Designed with a deep understanding of the challenges laboratories face, VeraPoint Urinary Max and AMR Max panels are comprehensive solutions for the detection of UTI pathogens and AMR genes. These panels leverage multiplexing, internal controls, and modular flexibility to meet the unique needs of any laboratory.

With the ability to identify 29 of the most common UTI-causing pathogens and 18 antimicrobial resistance genes covering 8 major drug classes, VeraPoint Urinary Max and VeraPoint AMR Max panels feature a broad target range to address the increasingly advanced needs of the field.

VeraPoint Urinary Max and VeraPoint AMR Max detect up to three targets per well, reducing sample volume requirements, reagent waste, and workflow complexity. This multiplexing capability enables laboratories to streamline operations by optimizing resources.

To ensure confidence in every run, VeraPoint Urinary Max and AMR Max are equipped with internal controls in every mix. These controls validate sample integrity and reagent performance for consistent and accurate results.

Lusis’s comprehensive UTI solution is available in flexible configurations to adapt to different workflows:

• Flexible Panel Sizing: Small, medium, or large configurations optimize resource efficiency.
• Seamless AMR Integration: VeraPoint Urinary Max and VeraPoint AMR Max can be run concurrently in a single workflow for both pathogen and AMR detection, or VeraPoint AMR Max can be utilized as a reflex panel.
• Candida Add-On: VeraPoint Candida Core offers the option to add on species-specific Candida detection for expanded applications.

VeraPoint reagents are thoughtfully developed to balance performance and cost-efficiency. Designed to fit seamlessly into existing workflows, VeraPoint reagents empower laboratories to do more with less—without ever compromising quality.

“At Lusis, making molecular science more accessible is at the core of our mission," said Chi Chen, CEO of Lusis Biosciences. "Antibiotic resistance is a growing public health crisis, and urinary tract infections remain among the most common infections, with complicated cases on the rise. Industry standard methods like culture often take days and lack sensitivity, leading to delayed or incomplete treatment and recurring infections. VeraPoint Urinary Max and VeraPoint AMR Max address these challenges head-on, offering an advanced solution tailored to the demands of modern labs. This launch reaffirms our continued commitment to equipping labs with products that meet the highest standards.”

To learn more about VeraPoint UTI and AMR reagents and how they can support any laboratory workflow, visit lusisbio.com/uti.

VeraPoint reagents are for Research Use Only and are not intended for diagnostic applications.